We determined the concentration of proapolipoprotein (proapo) A-I and its ratio with total apolipoprotein(apo) A-I (proapo A-I/total apo A-I) in plasma of patients with liver disease; we used a noncompetitivesandwich method, an enzyme-linked immunosorbent assay. The mean (SD) proapo A-I concentrations in patients with decompensated or compensated liver cirrhosis were higher than in normal subjects: 88 (25), 105 (36), and 69 (25) mg/L, respectively. The mean (SD) ratio (expressed as %) for each of these types of liver cirrhosis was also higher than in normal subjects: 10.0 (3.5), 10.2 (3.9), and 4.6 (1.6), respectively. In the patients, the proapo A-I concentration was positively correlated with the concentration of highdensity lipoprotein subtype 2 cholesterol (HDL2-C) (r = 0.736), and the proapo A-I/total apo A-I ratio was correlated inversely with the HDL3-C concentration (r = -0.609). The activity of proapo A-I converting enzyme in patients with liver cirrhosis (62 ± 30 nmol/h per liter) was significantly (P <0.01) lower than that in normal subjects (172 ± 55 nmol/h per liter). The increases of the plasma proapo A-I concentration and ratio in patients with liver cirrhosis may be caused by a decreased production of the converting enzyme in the liver. The increase of plasma proapo A-I may thus also affect the circulating HDL subtypes.
in liver disease because no simple, sensitive assay for this was available until recently.
In the present study, we measured proape A-I in plasma of patients with advanced liver disorders, using an enzyme-linked immunosorbent assay (ELISA) as doscribed by Barkia et al. (11) . We also explored whether the plasma proape A-I affects HDL metabolism, as reflected by the HDL subtypes in circulation.
Subjects and Methods

Subjects
We studied 23 patients with liver cirrhosis, 9 with chronic hepatitis, and 21 normal subjects. Their characteristics are summarized in Table 1 . The normal subjects showed no abnormal findings in a medical health examination, including results for blood chemistry tests.
The diagnoses of liver cirrhosis and chronic hepatitis were based on the biochemical data, abdominal echo studies, and computed tomography.
Six patients with continuous ascites or hepatic encephalopathy were considered to have decompensated liver cirrhosis. Table 2 shows the clinical data for the patients.
Methods
Blood from fasting subjects was collected in tubes containing Na2EDTA, 1 g/L; after centrifugation at 4#{176}C, the plasma was separated. In the experiment involving proapo A-I converting enzyme, fresh serum was obtained from the fasting subjects' blood samples without any anticoagulant. Proapo A-I and polyclonal apo A-I antibody. Monospecific anti-proape A-I rabbit antibodies were raised against a synthetic peptide according to Barkia (17) . After centrifugation, we measured the absor- 
Concentrations of plasma lipids and HDL cholesterol (HDL-C).
Plasma concentrations of total cholesterol, subfraction cholesterol (HDL-C, HDL2-C, and HDL3-C) concentrations were measured by the heparin-Mn2 and dextran sulfate precipitation method of Gidez et al. (18) HDL-C, especially HDL3-C, were significantly lower (P <0.01) than those in the normal group (Table 3) . Total ape A-I concentrations also were significantly lower (P <0.01) in the liver cirrhosis patients than in those in the normal group (Table 4) . Proapo A-I concentrations were significantly higher in the groups with compensated liver cirrhosis (P <0.01) and chronic hepatitis (P <0.02) than in the normal group; those in the group of decompensated liver cirrhosis patients were not significantly different from normal. Proape/total ape A-I ratios were significantly (P <0.01) higher (more than double) in the groups with liver cirrhosis than in the normal group; the ratios in the patients with chronic hepatitis were also higher, but not significantly so. Table 5 
Results
Specificity
Discussion
We measured proape A-I by the modified ELISA described by Barkia et al. (11) . We used the ELISA because it was specific for proapo A-I, rapid, and sensitive.
Although there are but few examples of extracellular proprotein processing, proapo A-I is converted to mature ape A-I extracellularly (3, 4, 7, 20) . In proape A-I, the COOH-terminal sequence of propeptide is Gln-Glndifferent from other known propeptide sequences, which generally have COOH-terminal paired basic amino acids. Despite the determination of these proapo A-I characteristics, the role of the proprotein on lipoprotein metabolism
is not yet fully understood.
Our results
show that the plasma concentration of proape A-I in the patients with advanced liver disorders was indeed increased, despite the decrease of total ape A-I concentrations in plasma. Because most of plasma proape A-I is converted to mature ape A-I without catabolism (7, 21) , the proapo A-I concentration is regulated by both the rate of synthesis in the liver and intestine and the converting rate in the circulation. Therefore, the increase of proape A-I in the patients with advanced liver disorders may be partly due to the change in converting rate. The proape/total ape A-I ratio reflects the proapo A-I converting activity independently of the proape A-I synthesis rate. In our study, the increase of the ratio in liver cirrhosis was more than twice that in normal subjects and indicated a considerable disturbance to the conversion process in this disease. Furthermore, this ratio correlated with the extent of liver functions. Therefore, converting activity may decrease with the We calculated the converting enzyme activity from the in vitro changes of serum proapo A-I concentration after incubation at 37#{176}C. The converting ratio after 6 h in normal subjects by this method was about 36%, which agrees with the result of Ghiselli and Sherrill (25) , who measured the activity in vitro by using 125I-labeled proapo A-I. In liver cirrhosis patients, this activity was only about one-third of that in normal subjects. #{149} .
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A-I. The change may play a part in the maturation of the discoidal structures, which are converted to HDL3 in the presence of LCAT. Our results indicate a correlation between the increase of proape/total ape A-I ratio and the decrease of HDL3 in advanced liver diseases. On the other hand, plasma proapo A-I concentrations in liver cirrhosis were correlated positively with HDL2-C coilcentrations. If the cleavage is disturbed by a decrease of converting enzyme activity, the production of new HDL3 particles may not be complete, and HDL2 in the presence of proape A-I instead of mature ape A-I may change its surface structure such that its metabolism is affected. However, there was no significant difference in the proape A-I ratio in the HDL2 and HDL3 fractions separated by ultracentrifligation from the plasma of another five patients (data not shown). Therefore, the increase of proapo A-I may only slightly influence the HDL2 and HDL3 particles. Further studies are required to determine the relation between proape A-I and circulating HDL subtypes.
